429 related articles for article (PubMed ID: 21718738)
1. Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix(®)) in adults 55 years of age and over: a sub-analysis of four trials.
Van Damme P; McIntyre P; Grimprel E; Kuriyakose S; Jacquet JM; Hardt K; Messier M; Van Der Meeren O
Vaccine; 2011 Aug; 29(35):5932-9. PubMed ID: 21718738
[TBL] [Abstract][Full Text] [Related]
2. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.
Grimprel E; von Sonnenburg F; Sänger R; Abitbol V; Wolter JM; Schuerman LM
Vaccine; 2005 May; 23(28):3657-67. PubMed ID: 15882526
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine as a single-dose booster in Singaporean adults.
Chan SH; Tan PT; Han HH; Bock HL
Singapore Med J; 2006 Apr; 47(4):286-90. PubMed ID: 16572239
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and reactogenicity of a decennial booster dose of a combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and inactivated poliovirus booster vaccine (dTpa-IPV) in healthy adults.
Kovac M; Rathi N; Kuriyakose S; Hardt K; Schwarz TF
Vaccine; 2015 May; 33(22):2594-601. PubMed ID: 25882172
[TBL] [Abstract][Full Text] [Related]
5. Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization.
McCormack PL
Drugs; 2012 Sep; 72(13):1765-91. PubMed ID: 22931522
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
Lee SY; Hwang HS; Kim JH; Kim HH; Lee HS; Chung EH; Park SE; Ma SH; Chang JK; Guitton F; Ortiz E; Kang JH
Vaccine; 2011 Feb; 29(8):1551-7. PubMed ID: 21215828
[TBL] [Abstract][Full Text] [Related]
7. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
[TBL] [Abstract][Full Text] [Related]
8. Acellular pertussis vaccine boosters combined with diphtheria and tetanus toxoid boosters for adolescents: safety and immunogenicity assessment when preceded by different 5-dose DTaP/DTwP schedules.
Pichichero ME; Casey JR; Francis AB; Marsocci SM; Murphy M; Hoeger W; Cleary C
Clin Pediatr (Phila); 2006 Sep; 45(7):613-20. PubMed ID: 16928838
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of SIIPL Tdap, a new tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, in healthy subjects 4-65 years of age: A Phase II/III randomized, observer-blinded, active controlled, multicenter clinical study in Germany.
Aydin I; May M; Pisano F; Mpofu-Maetzig N; Grode L; Parekh S; Pujari P; Shewale S; Desai S; Sharma H; Rao H; Gautam M; Gairola S; Shaligram U
Vaccine; 2023 Nov; 41(46):6810-6819. PubMed ID: 37827966
[TBL] [Abstract][Full Text] [Related]
10. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine.
Lin TY; Wang YH; Huang YC; Chiu CH; Lin PY; Chen CJ; Chavand P; Ortiz E
Int J Infect Dis; 2007 Nov; 11(6):488-95. PubMed ID: 17349809
[TBL] [Abstract][Full Text] [Related]
11. Reduced-antigen, combined diphtheria, tetanus, and acellular pertussis vaccine (Boostrix): a review of its use as a single-dose booster immunization.
Frampton JE; Keating GM
BioDrugs; 2006; 20(6):371-89. PubMed ID: 17176125
[TBL] [Abstract][Full Text] [Related]
12. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A
Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304
[TBL] [Abstract][Full Text] [Related]
13. Primary and booster immunization with a diphtheria, tetanus, acellular pertussis, hepatitis B (DTPa-HBV) and Haemophilus influenzae type b (Hib) vaccine administered separately or together is safe and immunogenic.
Marshall H; McIntyre P; Roberton D; Dinan L; Hardt K
Int J Infect Dis; 2010 Jan; 14(1):e41-9. PubMed ID: 19467896
[TBL] [Abstract][Full Text] [Related]
14. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older - Advisory Committee on Immunization Practices (ACIP), 2012.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2012 Jun; 61(25):468-70. PubMed ID: 22739778
[TBL] [Abstract][Full Text] [Related]
15. Combined, reduced-antigen content tetanus, diphtheria, and acellular pertussis vaccine (Boostrix): a review of its use as a single-dose booster immunization in individuals aged 10-64 years in the US.
Plosker GL
BioDrugs; 2009; 23(4):253-67. PubMed ID: 19697967
[TBL] [Abstract][Full Text] [Related]
16. Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults.
Mertsola J; Van Der Meeren O; He Q; Linko-Parvinen A; Ramakrishnan G; Mannermaa L; Soila M; Pulkkinen M; Jacquet JM
Clin Infect Dis; 2010 Sep; 51(6):656-62. PubMed ID: 20704493
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of one dose of diphtheria, tetanus, acellular pertussis and poliomyelitis vaccine (Repevax®) followed by two doses of diphtheria, tetanus and poliomyelitis vaccine (Revaxis®) in adults aged ≥ 40 years not receiving a diphtheria- and tetanus-containing vaccination in the last 20 years.
Dominicus R; Galtier F; Richard P; Baudin M
Vaccine; 2014 Jun; 32(31):3942-9. PubMed ID: 24852717
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip) to adults aged ≥60 years: an open-label, randomised trial.
Zimmermann U; Gavazzi G; Richard P; Eymin C; Soubeyrand B; Baudin M
Vaccine; 2013 Mar; 31(11):1496-502. PubMed ID: 23313654
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of reduced antigen content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
Zepp F; Habermehl P; Knuf M; Mannhardt-Laakman W; Howe B; Friedland LR
Vaccine; 2007 Jul; 25(29):5248-52. PubMed ID: 17583395
[TBL] [Abstract][Full Text] [Related]
20. Persistence of antibodies 3 years after booster vaccination of adults with combined acellular pertussis, diphtheria and tetanus toxoids vaccine.
Weston W; Messier M; Friedland LR; Wu X; Howe B
Vaccine; 2011 Nov; 29(47):8483-6. PubMed ID: 21945698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
